Targeting Tumor-Associated Macrophages in Cancer Immunotherapy

被引:38
|
作者
Petty, Amy J. [1 ]
Owen, Dwight H. [2 ,3 ]
Yang, Yiping [3 ,4 ]
Huang, Xiaopei [3 ,4 ]
机构
[1] Duke Univ, Dept Med, Med Ctr, Durham, NC 27710 USA
[2] Ohio State Univ, Div Med Oncol, Dept Internal Med, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, OSU Comprehens Canc Ctr, Columbus, OH 43210 USA
[4] Ohio State Univ, Div Hematol, Dept Internal Med, Coll Med, Columbus, OH 43210 USA
关键词
tumor-associated macrophages (TAM); tumor microenvironment; immunotherapy; checkpoint inhibitor; cancer; REGULATORY T-CELLS; CHEMOKINE LIGAND 2; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN MONOCLONAL-ANTIBODY; ENDOTHELIAL GROWTH-FACTOR; CARLUMAB CNTO 888; OPEN-LABEL; PANCREATIC-CANCER; ANGIOGENIC SWITCH; IMMUNE PRIVILEGE;
D O I
10.3390/cancers13215318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Tumor-associated macrophages (TAMs) coinhabit the tumor microenvironment with cancer, immune, and stromal cells. They undermine the immune system and facilitate tumor growth and metastasis. In this review, we discussed current understanding of TAMs functions, and strategies harnessing the knowledge gained from recent research to develop innovative cancer treatments. We summarized pre-clinical/clinical studies targeting TAMs with small molecule inhibitors or antibodies alone or combined with chemotherapy/immunotherapy, evaluated the efficacy of these therapies, and discussed mechanisms of actions.Tumor-associated macrophages (TAMs) represent the most abundant leukocyte population in most solid tumors and are greatly influenced by the tumor microenvironment. More importantly, these macrophages can promote tumor growth and metastasis through interactions with other cell populations within the tumor milieu and have been associated with poor outcomes in multiple tumors. In this review, we examine how the tumor microenvironment facilitates the polarization of TAMs. Additionally, we evaluate the mechanisms by which TAMs promote tumor angiogenesis, induce tumor invasion and metastasis, enhance chemotherapeutic resistance, and foster immune evasion. Lastly, we focus on therapeutic strategies that target TAMs in the treatments of cancer, including reducing monocyte recruitment, depleting or reprogramming TAMs, and targeting inhibitory molecules to increase TAM-mediated phagocytosis.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape
    Wang, Zide
    Zhong, Hanlin
    Liang, Xiaohong
    Ni, Shilei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] Targeting the TAM receptors on prostate cancer tumor-associated macrophages
    Myers, Kayla V.
    Pienta, Kenneth J.
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Targeting tumor-associated macrophages in cancer therapy and understanding their complexity
    Cannarile, Michael A.
    Ries, Carola H.
    Hoves, Sabine
    Ruettinger, Dominik
    ONCOIMMUNOLOGY, 2014, 3 (09):
  • [44] Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy
    Chen, Yu-Jia
    Li, Guan-Nan
    Li, Xian-Jing
    Wei, Lin -Xing
    Fu, Min-Jie
    Cheng, Zhou-Li
    Yang, Zhen
    Zhu, Gui-Qi
    Wang, Xu-Dong
    Zhang, Cheng
    Zhang, Jin-Ye
    Sun, Yi-Ping
    Saiyin, Hexige
    Zhang, Jin
    Liu, Wei-Ren
    Zhu, Wen -Wei
    Guan, Kun-Liang
    Xiong, Yue
    Yang, Yong
    Ye, Dan
    Chen, Lei-Lei
    SCIENCE ADVANCES, 2023, 9 (17)
  • [45] Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy
    Vanmeerbeek, Isaure
    Naulaerts, Stefan
    Sprooten, Jenny
    Laureano, Raquel S.
    Govaerts, Jannes
    Trotta, Rosa
    Pretto, Samantha
    Zhao, Shikang
    Cafarello, Sarah Trusso
    Verelst, Joren
    Jacquemyn, Maarten
    Pociupany, Martyna
    Boon, Louis
    Schlenner, Susan M.
    Tejpar, Sabine
    Daelemans, Dirk
    Mazzone, Massimiliano
    Garg, Abhishek D.
    SCIENCE ADVANCES, 2024, 10 (29):
  • [46] Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel
    Dai, Xiaomeng
    Meng, Jingshu
    Deng, Suke
    Zhang, Lingling
    Wan, Chao
    Lu, Lisen
    Huang, Jing
    Hu, Yan
    Zhang, Zhanjie
    Li, Yan
    Lovell, Jonathan F.
    Wu, Gang
    Yang, Kunyu
    Jin, Honglin
    THERANOSTICS, 2020, 10 (07): : 3049 - 3063
  • [47] Reprogramming Hypoxic Tumor-Associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy
    Zhao, Yong-Dan
    An, Hong-Wei
    Mamuti, Muhetaerjiang
    Zeng, Xiang-Zhong
    Zheng, Rui
    Yang, Jia
    Zhou, Wei
    Liang, Yuxin
    Qin, Gege
    Hou, Da-Yong
    Liu, Xiaolong
    Wang, Hao
    Zhao, Yuliang
    Fang, Xiaohong
    ADVANCED MATERIALS, 2023, 35 (24)
  • [48] Tumor-Associated Carbohydrate Antigens Targeting Immunotherapy
    Matsumoto, Yasuyuki
    TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, 2021, 33 (192) : E33 - E38
  • [49] Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages
    Ovais, Muhammad
    Guo, Mengyu
    Chen, Chunying
    ADVANCED MATERIALS, 2019, 31 (19)
  • [50] Tailoring nanomaterials for targeting tumor-associated macrophages
    Ovais, M.
    Guo, M.
    Chen, C.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 534 - 534